Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Notes from the Field: Increase in Fentanyl-Related Overdose Deaths — Rhode Island, November 2013–March 2014

Melissa C. Mercado-Crespo, PhD1, Steven A. Sumner, MD1, M. Bridget Spelke2, David E. Sugerman, MD2, Christina Stanley, MD3 (Author affiliations at end of text)

During November 2013–March 2014, twice as many all-intent drug overdose deaths were reported in Rhode Island as were reported during the same period in previous years. Most deaths were among injection-drug users, and a large percentage involved fentanyl, a synthetic opioid that is 50–100 times more potent than morphine (1). Clusters of fentanyl-related deaths have been reported recently in several states. From April 2005 to March 2007, time-limited active surveillance from CDC and the Drug Enforcement Administration identified 1,013 deaths caused by illicit fentanyl use in New Jersey; Maryland; Chicago, Illinois; Detroit, Michigan; and Philadelphia, Pennsylvania (2). Acetyl fentanyl, an illegally produced fentanyl analog, caused a cluster of overdose deaths in northern Rhode Island in 2013 (3).

The Rhode Island Department of Health (RIDOH) requested CDC's assistance in describing and determining risk factors for recent fentanyl-related overdose death cases. CDC abstracted records from RIDOH's Office of State Medical Examiners, Division of Vital Records, and Prescription Monitoring Program, with the assistance of local staff members. A fentanyl-related overdose death was defined as a death that occurred during November 2013–March 2014 in which fentanyl was listed as the official cause of death, a contributor to the cause of death, or in which toxicology reports identified fentanyl levels above the detection limit (≥2 ng/mL) by enzyme-linked immunosorbent assay.

Preliminary analyses show that fentanyl-related overdose deaths accounted for 52 (31.5%) of the 165 unintentional overdose deaths reported during November 2013–March 2014. Most decedents did not have active fentanyl prescriptions; the fentanyl appeared to originate from illicit sources and was not acetyl fentanyl–related. Although fentanyl-related overdose deaths were widespread in Rhode Island, most cases occurred in Providence and surrounding urban areas. CDC is currently conducting additional data analyses to determine whether the prescription monitoring program records or medical records of the decedents might help identify others at high risk for similar outcomes.

CDC collaborated with RIDOH to develop an emergency regulation that requires all Rhode Island emergency departments to report fatal and nonfatal opioid overdose cases within 48 hours to RIDOH. CDC recommended that RIDOH continue and expand its efforts to make naloxone, a prescription drug that helps reverse the effects of opioids, accessible for prior drug overdose patients and their families.

1EIS officer, CDC; 2Division of Unintentional Injury Prevention, National Center for Injury Prevention and Control, CDC; 3Office of the State Medical Examiners, Rhode Island Department of Health (Corresponding author: Melissa C. Mercado-Crespo, mmercadocrespo@cdc.gov, 770-488-4713)

References

  1. Drug Enforcement Administration, US Department of Justice. Control of a chemical precursor used in the illicit manufacture of fentanyl as a List I chemical. Final rule. Fed Regist 2008;73:43355–7.
  2. CDC. Nonpharmaceutical fentanyl-related deaths—multiple states, April 2005–March 2007. MMWR 2008;57:793–6.
  3. CDC. Acetyl fentanyl overdose fatalities—Rhode Island, March–May 2013. MMWR 2013;62:703–4.


Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites. URL addresses listed in MMWR were current as of the date of publication.


All MMWR HTML versions of articles are electronic conversions from typeset documents. This conversion might result in character translation or format errors in the HTML version. Users are referred to the electronic PDF version (http://www.cdc.gov/mmwr) and/or the original MMWR paper copy for printable versions of official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices.

**Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.

 
USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO
A-Z Index
  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
  27. #